Pharmaceutical

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Solid Tumor.

Dec 22, 2023 - 18:00
Iruplinalkib is under clinical development by Qilu Pharmaceutical and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

IDE-161 by Ideaya Biosciences for Metastatic Ovarian Cancer: Likelihood of Approval

Next Article

XB-002 by Exelixis for Breast Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

Emergent to donate 20,000 Narcan doses to fight opioid ...

Oct 10, 2024

The science of viscous drug product filling: Pumps, pressure, and process optimization

The science of viscous drug product filling: Pumps, pre...

Oct 16, 2024

Ginkgo Bioworks and Merck partner to bolster biologic manufacturing

Ginkgo Bioworks and Merck partner to bolster biologic m...

Aug 8, 2023